Pasadena, California, United States, 29th Dec 2023 – Circularity Healthcare, an emerging leader in the health care industry, has announced a significant breakthrough in the treatment of chronic pain and underlying conditions such as fibromyalgia, arthritis, and non-healing diabetic foot wounds. This innovation, D’OXYVA® (deoxyhemoglobin vasodilator), a non-prescription, non-opioid solution, has shown remarkable results in alleviating severe chronic pain and enhancing cardiovascular, microvascular, and autonomic nervous system health.
The company’s approach has been especially effective for individuals struggling with severe neuropathy, chronic pain, fibromyalgia, arthritis, and various other chronic conditions. D’OXYVA®’s efficacy stems from its patented and patent pending formulation that utilizes carbon dioxide (CO2) also sourced from carbon capture processes as the main FDA-cleared active pharmaceutical ingredient (API). This not only makes the product environmentally sustainable, producing virtually zero waste, but also highly effective in treating the targeted conditions.
Circularity Healthcare’s commitment to affordable and accessible treatment aligns with the needs of most income levels, particularly when used as directed. The company has prioritized direct-to-consumer marketing, focusing on out-of-pocket business models that make the treatment more accessible to a wider range of patients.
The product has undergone extensive testing and research, demonstrating its safety and efficacy. Over 1 million applications of D’OXYVA® have been recorded in several dozen countries, with significant involvement from 18 of the top 20 U.S. universities in expanded pivotal trials. These trials have further established the product’s credibility and effectiveness, reinforcing its FDA-cleared status. An impressive 97% of users have reported life-changing benefits within 4-8 weeks of usage.
Circularity Healthcare’s product has been recommended by world-renowned experts, ensuring detectable benefits after each 5-minute application. The company is so confident in the efficacy of D’OXYVA® that they offer a full refund if quantifiable results do not improve within 30 days with twice-daily applications.
This groundbreaking solution has been clinically proven to provide full-body benefits through a topical spray application. It has shown lasting relief of severe chronic pain within 2-4 weeks and substantial improvement in underlying chronic complications in 4-8 weeks. Additionally, it has demonstrated significant improvements in the appearance of severe spider and varicose veins, as well as enhanced efficacy in wound healing and stamina.
Backed by 10 years of sterling evidence, all completed human studies have demonstrated exceptional results without a single adverse event report. The product’s effectiveness is underscored by its success in managing complex health complications for over 97% of a wide variety of enrolled patients and regular daily users.
Mr. Norbert Kiss, President & CEO of Circularity Healthcare, stated, “The achievements of D’OXYVA® are a testament to our commitment to revolutionizing health care through scientific breakthroughs. Our continued dedication to medical research is shaping the future of healthcare, offering hope and effective treatment options to individuals facing various health challenges.”
Media Contact
Organization: Circularity Healthcare
Contact Person: Norbert Kiss
Website: https://www.circularityhealthcare.com/
Email: Send Email
Contact Number: 1-888-8DOXYVA
City: Pasadena
State: California
Country: United States
Release Id: 2912238557